CAI Caris Life Sciences Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: CAI
  4. Earnings
?
Relative Growth: Rel. Growth: 64
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 57
Relative Profitability: Rel. Profitability: 93

EPS in 2026 (TTM): $1.7

Last Report Period Date: Jun 30, 2026

Currently, CAI's 12-month EPS stands at $1.7, according to the most recent financial reports. During 2025, CAI reported a per-share earnings of -$3.22, which shows a rise compared to the EPS of -$10.66 recorded in 2024. CAI recorded an EPS of $0 for the quarterly period ending on Jun 30, 2026.

CAI earnings history

Historical annual and quarterly earnings per share (EPS) data for Caris Life Sciences
EPS (TTM)
$1.7
EPS Growth YoY (Quarterly)
100%
EPS (Quarterly)
$0
EPS Growth (Quarterly)
N/A

In 2025, Caris Life Sciences's earnings per share was -$3.22, a rise of 69.8% from -$10.66 in 2024. Over the quarter ending Jun 30, 2026, the earnings per share came in at $0, reflecting a 100% increase compared to the same quarter a year earlier. As of June 2026, the TTM EPS is $1.7. During 2024, the annual earnings per share was -$10.66, representing an increase of 19.5% compared to 2023.

CAI EPS vs price chart

CAI EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
100%
EPS growth YoY
69.8%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Caris Life Sciences has recorded a growth in earnings per share of 100% in the past 12 months (YoY, quarterly).

CAI Earnings Waterfall

Breakdown of revenue, profit and net income for Caris Life Sciences

CAI Earnings vs Peers

What are the earnings of CAI compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
CAI Caris Life Sciences Inc. 18.62 69.8% N/A N/A
DGX Quest Diagnostics Inc 24.42 14% 3.1% -3.5%
BIO Bio-Rad Laboratories Inc - Class A 47.07 142.6% N/A -26.3%
ILMN Illumina Inc 47.29 171.1% N/A 4.1%
GH Guardant Health Inc N/A 6.7% N/A N/A
QDEL QuidelOrtho Corporation N/A 45.4% N/A N/A
MYGN Myriad Genetics Inc N/A -180.1% N/A N/A
NEO Neogenomics Inc N/A -35.5% N/A N/A
NTRA Natera Inc N/A 0.7% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.